Elanco Animal Health (NYSE:ELAN) Hits New 52-Week Low at $20.45

Elanco Animal Health Incorporated (NYSE:ELANGet Rating) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $20.45 and last traded at $21.01, with a volume of 217506 shares trading hands. The stock had previously closed at $20.90.

A number of analysts have issued reports on the company. Barclays lifted their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Monday, February 28th. The Goldman Sachs Group reduced their price objective on Elanco Animal Health from $37.00 to $32.00 and set a “buy” rating on the stock in a research note on Thursday, May 19th. Finally, Morgan Stanley dropped their target price on Elanco Animal Health to $37.00 and set an “overweight” rating for the company in a report on Tuesday, May 17th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $34.60.

The stock has a market cap of $9.93 billion, a PE ratio of -28.53, a PEG ratio of 1.09 and a beta of 0.74. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.41 and a current ratio of 2.44. The stock has a fifty day moving average price of $24.33 and a 200 day moving average price of $26.16.

Elanco Animal Health (NYSE:ELANGet Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.01. Elanco Animal Health had a positive return on equity of 6.61% and a negative net margin of 7.65%. The company had revenue of $1.23 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same quarter in the previous year, the business earned $0.37 EPS. Elanco Animal Health’s revenue was down 1.4% compared to the same quarter last year. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.17 earnings per share for the current fiscal year.

In other Elanco Animal Health news, Director R David Hoover acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 20th. The stock was bought at an average price of $23.33 per share, for a total transaction of $233,300.00. Following the acquisition, the director now directly owns 125,000 shares in the company, valued at $2,916,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the business. Herold Advisors Inc. purchased a new position in Elanco Animal Health during the first quarter worth approximately $26,000. CKW Financial Group purchased a new position in Elanco Animal Health during the fourth quarter worth approximately $30,000. Tcwp LLC purchased a new position in Elanco Animal Health during the first quarter worth approximately $29,000. IndexIQ Advisors LLC purchased a new position in Elanco Animal Health during the first quarter worth approximately $32,000. Finally, Benjamin Edwards Inc. boosted its position in Elanco Animal Health by 157.1% during the fourth quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company’s stock worth $40,000 after purchasing an additional 872 shares in the last quarter.

Elanco Animal Health Company Profile (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Featured Articles

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.